BioRestorative Therapies公司近日更新了其核心研发管线的时间表。该公司目前预期,其备受关注的三期临床试验的新药研究申请(IND),计划在2026年下半年正式提交。这一进展标志着其在研疗法向商业化迈出了关键一步。
BioRestorative Therapies公司近日更新了其核心研发管线的时间表。该公司目前预期,其备受关注的三期临床试验的新药研究申请(IND),计划在2026年下半年正式提交。这一进展标志着其在研疗法向商业化迈出了关键一步。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.